Vusolimogene Oderparepvec + Nivolumab + Nivolumab + Relatlimab + Pembrolizumab + Single-agent chemotherapy
Phase 3Recruiting 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Melanoma
Conditions
Advanced Melanoma
Trial Timeline
Jul 11, 2024 → Aug 31, 2034
NCT ID
NCT06264180About Vusolimogene Oderparepvec + Nivolumab + Nivolumab + Relatlimab + Pembrolizumab + Single-agent chemotherapy
Vusolimogene Oderparepvec + Nivolumab + Nivolumab + Relatlimab + Pembrolizumab + Single-agent chemotherapy is a phase 3 stage product being developed by Replimune for Advanced Melanoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06264180. Target conditions include Advanced Melanoma.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06264180 | Phase 3 | Recruiting |
Competing Products
20 competing products in Advanced Melanoma